Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sweet syndrome with multiorgan involvement exacerbated by gilteritinib.
Jiménez-Sánchez A, Olivares-Guerrero M, Aparicio-Domínguez M, Berenguer-Ruiz S, Juárez-Salcedo LM, Muñoz-Hernández P, Gallardo F, Bellosillo B, Llamas-Velasco M. Jiménez-Sánchez A, et al. Among authors: llamas velasco m. Leuk Lymphoma. 2024 Nov 14:1-7. doi: 10.1080/10428194.2024.2426061. Online ahead of print. Leuk Lymphoma. 2024. PMID: 39540395 No abstract available.
Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study.
Martorell-Calatayud A, Santos-Alarcón S, Sahuquillo-Torralba A, Rivera-Díaz R, Belinchón-Romero I, Ruiz-Genao D, Romero-Maté A, Ruiz-Villaverde R, Ferran-Farrés M, Gallardo-Hernández F, Almenara-Blasco M, Suarez-Perez JA, González-Cantero Á, Martínez-Lorenzo E, Fernández-Armenteros JM, Del Alcázar-Viladomiu E, García-Latasa J, Rocamora-Durant V, Ara-Martín M, Mateu-Puchades A, Llamas-Velasco M, Vilarrasa E, Velasco-Pastor M, De la Cueva P, Carrascosa JM, Magdaleno-Tapial J. Martorell-Calatayud A, et al. Among authors: llamas velasco m. Actas Dermosifiliogr. 2024 Oct 23:S0001-7310(24)00854-8. doi: 10.1016/j.ad.2024.10.042. Online ahead of print. Actas Dermosifiliogr. 2024. PMID: 39454868 English, Spanish.
[Translated article] Measurement Assessment of Minimal Disease Activity in Psoriasis in Spain: A National Cross-Sectional Study.
Carretero Hernández G, Ara Martín M, Armesto Alonso S, Belinchón Romero I, Eiris Salvado N, Ferrán Farrés M, Galache Osuna C, García Bustínduy M, García Latasa de Araníbar J, Juliá Manresa M, Llamas Velasco M, López Ferrer A, Roncero Riesco M, Ruiz Genao D, Ruíz-Villaverde R, Salgado Boquete L, Soria Martínez C, Vilarrasa Rull E, Descalzo MA; AEDV Psoriasis Group. Carretero Hernández G, et al. Among authors: llamas velasco m. Actas Dermosifiliogr. 2024 Oct 9:S0001-7310(24)00766-X. doi: 10.1016/j.ad.2024.10.009. Online ahead of print. Actas Dermosifiliogr. 2024. PMID: 39389350 English, Spanish.
A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement.
Lebwohl M, Bukhalo M, Stein Gold L, Glick B, Llamas-Velasco M, Sanchez-Rivera S, Pan A, Zhan T, Drogaris L, Douglas K, St John G, Espaillat R, Bissonnette R. Lebwohl M, et al. Among authors: llamas velasco m. J Am Acad Dermatol. 2024 Dec;91(6):1150-1157. doi: 10.1016/j.jaad.2024.07.1521. Epub 2024 Aug 30. J Am Acad Dermatol. 2024. PMID: 39208985 Free article. Clinical Trial.
Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice.
Butrón-Bris B, Llamas-Velasco M, Ovejero-Benito MC, Santos-Juanes J, Martínez-López A, Ruiz-Villaverde R, Roustan G, Baniandrés O, Izu-Belloso R, de la Cueva P, Sahuquillo-Torralba A, Gónzalez-Quesada A, Vilarrasa-Rull E, Pujol-Montcusí J, García-Martínez J, Navares M, Palomar-Moreno I, Novalbos J, Abad-Santos F, Daudén E, de la Fuente H. Butrón-Bris B, et al. Among authors: llamas velasco m. Exp Dermatol. 2024 Aug;33(8):e15152. doi: 10.1111/exd.15152. Exp Dermatol. 2024. PMID: 39081053 Free PMC article.
[Translated article] Ruxolitinib and Squamous Cell Carcinoma.
Soto-García D, González-Sixto B, Suh-Oh HJ, Llamas-Velasco M, Rodríguez-Acevedo N, Flórez Á. Soto-García D, et al. Among authors: llamas velasco m. Actas Dermosifiliogr. 2024 Sep;115(8):T830-T833. doi: 10.1016/j.ad.2024.07.004. Epub 2024 Jul 5. Actas Dermosifiliogr. 2024. PMID: 38972579 Free article. English, Spanish. No abstract available.
Measurement Assessment of Minimal Disease Activity In Psoriasis in Spain: A National Cross-Sectional Study.
Carretero Hernández G, Ara Martín M, Armesto Alonso S, Belinchón Romero I, Eiris Salvado N, Ferrán Farrés M, Galache Osuna C, García Bustínduy M, García Latasa de Araníbar J, Juliá Manresa M, Llamas Velasco M, López Ferrer A, Roncero Riesco M, Ruiz Genao D, Ruíz-Villaverde R, Salgado Boquete L, Soria Martínez C, Vilarrasa Rull E, Descalzo MA; en representación del Grupo de Psoriasis de la AEDV. Carretero Hernández G, et al. Among authors: llamas velasco m. Actas Dermosifiliogr. 2024 Jun 12:S0001-7310(24)00507-6. doi: 10.1016/j.ad.2024.05.022. Online ahead of print. Actas Dermosifiliogr. 2024. PMID: 38876209 English, Spanish.
Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study.
Chiricozzi A, Coscarella G, Puig L, Vender R, Yeung J, Carrascosa JM, Piaserico S, Gisondi P, Lynde C, Ferreira P, Bastos PM, Dauden E, Leite L, Valerio J, Del Alcázar-Viladomiu E, Vilarrasa E, Llamas-Velasco M, Alessandri-Bonetti M, Messina F, Bruni M, Di Brizzi EV, Ricceri F, Nidegger A, Hugo J, Mufti A, Daponte AI, Teixeira L, Balato A, Romanelli M, Prignano F, Gkalpakiotis S, Conrad C, Lazaridou E, Rompoti N, Stratigos AJ, Nogueira M, Peris K, Torres T. Chiricozzi A, et al. Among authors: llamas velasco m. J Eur Acad Dermatol Venereol. 2024 Nov;38(11):2175-2185. doi: 10.1111/jdv.20143. Epub 2024 Jun 11. J Eur Acad Dermatol Venereol. 2024. PMID: 38860729
[Translated article] Comparing the Use of Topical Therapy Along with Anti-IL-17 and Anti-IL-23 to Treat Moderate-to-Severe Psoriasis in the Routine Clinical Practice.
Berenguer-Ruiz S, Romero-Dávila M, Aparicio-Domínguez M, Olivares-Guerrero M, Daudén E, Llamas-Velasco M. Berenguer-Ruiz S, et al. Among authors: llamas velasco m. Actas Dermosifiliogr. 2024 Jul-Aug;115(7):T647-T653. doi: 10.1016/j.ad.2024.05.008. Epub 2024 May 28. Actas Dermosifiliogr. 2024. PMID: 38815679 Free article. English, Spanish.
Certolizumab pegol effectiveness, survival and safety in patients with psoriasis: A multicenter retrospective analysis in daily clinical practice by the Spanish Psoriasis Group.
Sahuquillo-Torralba A, Mansilla-Polo M, Pujol-Marco C, Llamas-Velasco M, Rull EV, Ruiz Villaverde R, Ferran M, Pitarch G, Lopez A, Beltran E, Urruticoechea-Arana A, Riera-Monroig J, Alsina M, Vidal D, Belinchón Romero I, Notario J, Carrascosa JM, Gonzalez-Delgado V, Mollet J, Ribera M, Gallardo F. Sahuquillo-Torralba A, et al. Among authors: llamas velasco m. Int J Dermatol. 2024 Dec;63(12):1720-1727. doi: 10.1111/ijd.17238. Epub 2024 May 12. Int J Dermatol. 2024. PMID: 38736107
234 results